NCT04965753 2025-03-04
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Foghorn Therapeutics Inc.
Phase 1 Terminated
Clinical Trials
6 trialsNCT03604783 2024-09-19
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1 Terminated
NCT04176016 2024-02-02
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
OncoTherapy Science, Inc.
Phase 1 Terminated
NCT04145700 2023-09-13
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Eli Lilly and Company
Phase 1/2 Terminated
NCT00543712 2022-12-13
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
Genentech, Inc.
Phase 2 Terminated
NCT02609984 2020-07-07
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated